MSK Department of Medicine
@MSK_DeptOfMed
Followers
2K
Following
6K
Media
397
Statuses
3K
The official account of @MSKCancerCenter’s Department of Medicine. Chair/Dept. Head: @debschrag
New York, NY
Joined December 2021
.@PedramRazaviMD, a physician-scientist at MSK, explains MSK's efforts to prevent drug resistance from developing in #breastcancer patients. “In the past, we’ve always been reactive — we give a treatment, the cancer adapts to survive, and then we give a drug that blocks that
0
1
4
🚨The FDA has approved revumenib for patients with R/R AML and a susceptible NPM1 mutation. Read our latest article to learn more and to gain valuable insight into the AUGMENT-101 trial from Eytan Stein (@MSKCancerCenter): 👉 https://t.co/knopluG0iv 👈 #AMLsm #Leusm #Leukemia
1
5
7
Large real world dataset showing higher margin of benefit in non-GCB DLBCL. Glad to be part of this effort to fine tune #1LOT for #DLBCL. #lymsm @MSKCancerCenter @MSK_DeptOfMed
🚨Just out @CCR_AACR 🚨 V proud of our manuscript on polatuzumab efficacy by cell of origin in DLBCL We show COO by Hans predicts pola sensitivity in 740 pts Pts w R/R non-GCB DLBCL have higher ORR, CRR & PFS Massive thanks @dgermain21 & collabs! https://t.co/kGyRneMAuo
1
5
19
Pancreas folks peeking 👀 into #NSCLC neighbor’s #KRAS #G12D playbook to learn. Industries long feared our tough turf in #PDAC but it’s our time to rewrite the #PancreaticCancer story. Different modes of attacks⚔️, ONE mission. #PancreasWar #ForceIsStrong #MayTheTsBeWithU #RAS
1
6
30
12,963 Chinese physicians joined virtually for the “Lung Cancer Progress Highlights” during ESMO 2025. A heartfelt thank you to all the speakers for making this event a success! @HelenaYu923 @MSK_DeptOfMed @MSKCancerCenter @oncoOuLungCA @UCIrvineHealth #lungcancer #NSCLC
1
1
1
At ESMO Congress 2025 in Berlin, Dr. Helena Yu (MSKCC) presented key global Phase I data of the EGFR×HER3 bispecific ADC iza-bren (BL-B01D1) in NSCLC and solid tumors. eChinaHealth interviewed with Dr. Yu during the congress. @HelenaYu923 @MSK_DeptOfMed @MSKCancerCenter
0
1
2
🤝@MSKCancerCenter
@MSK_DeptOfMed #infectiousdiseases team X @MSKBiostats is well represented @IDWeekmtg 📣Proud to share our latest cutting-edge work on advancing care for #cancer patients from prevention to precision treatment 💉🩺🧬
0
1
1
🍾Congrats to Omar @abdelwahablab and his election to the @theNAMedicine🥼🧬. One of the GOATs 🐐of academic medicine! @MSK_DeptOfMed @MSKCancerCenter @MSKEducation
We're excited to share that Dr. Omar Abdel-Wahab, a leukemia specialist at Memorial Sloan Kettering Cancer Center (MSK) and Chair of the Molecular Pharmacology Program at Sloan Kettering Institute (SKI), has been elected to the @theNAMedicine (NAM). NAM elects members each year
2
1
26
#ESMO25 may be over, but #cancerresearch continues! Dr. Vicky Makker presented 5-year follow-up data from the 309/KEYNOTE-775 study that confirmed the efficacy and safety of lenvatinib & pembrolizumab in advanced #endometrialcancer. @MSKCancerCenter ➡️ https://t.co/xTsc41GIsk
1
5
22
🔥📣🎊@MSKCancerCenter
#infectiousdiseases Dr. Anna Kaltsas & @IHsinLin3 published a new study in @AnnSurgOncol evaluating risk factors for recurrent cellulitis in #BreastCancer patients with post-surgical lymphedema. Presenting @IDWeekmtg in ATL today! 🔗 https://t.co/1Lm5zvKFSP
0
4
4
This past weekend, MSK researchers presented exciting advances in medical oncology for a range of cancer types at the @myESMO Congress 2025 held in Berlin, Germany. Highlights included the latest updates on three phase 1 trials testing innovative treatment approaches for select
1
2
13
We had the exciting opportunity to sit down with @HardingJJMD of @MSKCancerCenter to discuss early-phase data with telisotuzumab adizutecan in PDAC and other difficult-to-treat tumors. Temab-A shows promising efficacy in MET-amplified tumors, highlighting the potential of
0
2
4
#HPB cancers focus of intense drug development. #ADC. Honor to represent @MSK_DeptOfMed @MSKCancerCenter
Phase 1 Basket Study of Telisotuzumab Adizutecan, a c-Met Protein–Targeting Antibody-Drug Conjugate: Results From PDAC cohort #ESMO25 #ESMOAmbassadors 👉 ORR: 23% 👉 mPFS: 5.4 mo 🧐interesting signal for Temab-A.... more options.... how to integrate with RAS inhibitors @myesmo
0
5
18
Rounding out the day's interview with Vicky Makker, MD, of @MSKCancerCenter, who expanded on updated data from the KEYNOTE-775 study, which confirmed long-term survival benefit with lenvatinib plus pembrolizumab in advanced endometrial cancer? Want to learn more? Keep an eye
1
2
5
Tomorrow at #ESMO25: MSK’s Dr. James Harding (@HardingJJMD) will present “Phase 1 basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC)” @myESMO
0
1
10
Next at #ESMO25: MSK’s Dr. Jamie Chaft will share about optimised adaptive strategies with systemic #immunotherapy. @myESMO Learn more: https://t.co/tNzYjmk8yc
1
2
8
Coming up at #ESMO25: MSK’s Dr. Carol Aghajanian will discuss present “Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival
0
1
9
Tomorrow morning at #ESMO25, join @WTapMD for a special symposium presentation on how to use biology to guide the development of novel therapies for #sarcoma. @MSKCancerCenter @myESMO Learn more: https://t.co/DsxzEWtCbx
0
0
3
At #ESMO25, join @YoninaMG to learn about the results of a phase 1 study that evaluated telisotuzumab adizutecan in patients with MET-amplified advanced solid tumors. @MSKCancerCenter @myESMO Learn more: https://t.co/g3FYOnS7Ei
0
2
8